ReShape Lifesciences Inc.

NASDAQ: RSLS · Real-Time Price · USD
3.92
0.72 (22.50%)
At close: Aug 14, 2025, 3:59 PM

ReShape Lifesciences Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
7.17M 8.01M 8.18M 8.05M 8.34M 8.68M 9.81M 10.45M 11.09M 11.24M 11.27M 12.18M 12.82M 13.6M 13.66M 13.56M 11.73M
Cost of Revenue
2.6M 2.95M 2.6M 2.62M 2.85M 3.13M 4.5M 4.33M 4.28M 4.44M 4.29M 5.17M 5.54M 5.25M 5.45M 5.2M 4.69M
Gross Profit
4.57M 5.06M 5.58M 5.43M 5.49M 5.55M 5.31M 6.12M 6.81M 6.8M 6.98M 7.01M 7.28M 8.35M 8.21M 8.36M 7.04M
Operating Income
-6.66M -6.67M -7.92M -9.26M -11.18M -14.61M -17.42M -26.61M -31.88M -34.65M -65.5M -68.19M -62.64M -56.5M -24.15M -11.34M -10.63M
Interest Income
5K 5K 21K 26K 31K 31K 14K 40K 45K 46K 46K 15K 1K n/a n/a n/a n/a
Pretax Income
-3.43M -7.09M -7M -8.96M -10.87M -11.34M -26.15M -35.17M -41.11M -46.84M -65.94M -71.12M -65.56M -62.04M -35.06M -22.55M -22.33M
Net Income
-3.46M -7.13M -7.07M -9.02M -10.92M -11.39M -26.3M -34.95M -40.9M -46.46M -65.3M -70.82M -65.27M -61.93M -35.01M -22.49M -22.19M
Selling & General & Admin
9.19M 9.92M 11.48M 12.53M 14.36M 17.87M 20.74M 23.28M 28.66M 31.12M 33.56M 42.72M 38.47M 33.57M 29.24M 17.28M 14.9M
Research & Development
1.68M 1.8M 2.02M 2.16M 2.35M 2.31M 2.02M 2.06M 2.22M 2.52M 2.35M 3.34M 2.7M 2.52M 3.12M 2.41M 2.77M
Other Expenses
367K 25K 25K 25K 31K 8K 10K 10K 3K 12K 10K 10K 11K n/a n/a n/a n/a
Operating Expenses
11.24M 11.72M 13.5M 14.69M 16.71M 20.19M 22.75M 25.34M 30.88M 33.64M 35.92M 46.06M 41.17M 36.1M 32.36M 19.7M 17.68M
Interest Expense
n/a n/a n/a n/a n/a 5K 3.99M 3.99M 3.99M 3.99M 28K 61K 233K 832K 1.22M 1.93M 2.54M
Selling & Marketing Expenses
2.5M 2.99M 3.81M 4.88M 6.38M 7.55M 8.25M 9.07M 11.53M 14.05M 14.93M 15.82M 12.62M 9.17M 7.44M 5.1M 4.49M
Cost & Expenses
13.84M 14.67M 16.1M 17.31M 19.55M 23.32M 27.25M 29.67M 35.16M 38.08M 40.21M 51.23M 46.71M 41.35M 37.81M 24.89M 22.36M
Income Tax Expense
33K 40K 66K 63K 52K 52K 152K -214K -209K -380K -640K -307K -288K -106K -51K -60K -138K
Shares Outstanding (Basic)
3.11K 515.57K 508.85K 434.87K 404.43K 404.43K 59.53K 56.02K 29.45K 8.08K 7.78K 6.66K 6.39K 6.16K 5.89K 1.57K 1.35K
Shares Outstanding (Diluted)
3.11K 515.57K 508.85K 434.87K 404.43K 404.43K 59.53K 56.02K 29.45K 8.08K 7.78K 6.66K 6.4K 6.16K 5.89K 1.57K 1.35K
EPS (Basic)
466.09 -13.83 -16.4 -72.45 -131.42 -216.48 -2.27K -3.78K -5.13K -6.33K -10.03K -11.46K -12.53K -14.84K -15.39K -16.21K -15.24K
EPS (Diluted)
466.09 -13.83 -16.4 -72.45 -131.42 -216.48 -2.27K -3.78K -5.13K -6.33K -10.03K -11.46K -12.53K -14.84K -15.39K -16.21K -15.24K
EBITDA
-6.28M -6.64M -7.9M -9.19M -11.11M -14.48M -28.4M -29.68M -34.03M -36.02M -55.21M -65.32M -60M -56.44M -24.64M -12.38M -11.96M
EBIT
-6.3M -6.67M -7.92M -9.26M -11.22M -14.64M -29.06M -30.83M -36.39M -39.13M -58.37M -68.48M -62.62M -58.41M -31.05M -20.54M -19.7M
Depreciation & Amortization
20K 22K 24K 69K 112K 154K 662K 1.16M 1.65M 2.15M 2.19M 2.2M 2.35M 1.97M 1.83M 1.7M 1.41M